Loading...
Study results on antipsychotic use in patients with borderline personality disorder have been conflicting, in part due to the many associated mood, anxiety, behavioral, and cognitive symptoms. In an industry-funded, multisite, double-blind study, academic researchers randomized 95 patients with borderline personality disorder to 8 weeks of extended-release quetiapine at 150 mg/day, 300 mg/day, or placebo (mean age, 29; 29% male).
Quetiapine dosing was started at 50 mg/day and gradually increased over several weeks. Exclusions were current substance dependence or recent abuse, recent suicidality, lifetime psychosis or neurological disorders, pregnancy, lactation, or previous nonresponse to atypical antipsychotics. Overall, 80% of patients had…